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Abstract Osteoporotic fracture healing is critical to
clinical outcome in terms of functional recovery, morbid-
ity, and quality of life. Osteoporosis treatments may affect
bone repair, so insights into their impact on fracture heal-
ing are important. We reviewed the current evidence for an
impact of osteoporosis treatments on bone repair. Treat-
ment with bisphosphonate in experimental models is
associated with increased callus size and mineralization,
reduced callus remodeling, and improved mechanical
strength. Local and systemic bisphosphonate treatment
may improve implant fixation. No negative impact on
fracture healing has been observed, even after major sur-
gery or when administered immediately after fracture.
Experimental data for denosumab and raloxifene suggest
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no negative implications for bone repair. The extensive
experimental results for teriparatide indicate increased
callus formation, improved biomechanical strength, and
greater external callus volume and total bone mineral
content and density. Case reports and a randomized trial
have produced mixed results but are consistent with a
positive impact of teriparatide on clinical fracture healing.
Studies with strontium ranelate in models of fracture
healing indicate that it is associated with improved bone
microstructure, callus volume, and biomechanical proper-
ties. Finally, there is experimental evidence for a beneficial
effect of some of the agents currently being developed for
osteoporosis, notably sclerostin antibody and DKK1 anti-
body. There is currently no evidence that osteoporosis
treatments are detrimental for bone repair and some
promising experimental evidence for positive effects on
healing, notably for agents with a bone-forming mode of
action, which may translate into therapeutic applications.
Keywords Fractures  Healing  Bone formation 
Osteoporosis  Treatment
The ultimate consequence of osteoporosis is fragility
fracture. The subsequent regeneration of bone occurs in
three stages, with inflammatory, reparative, and remodeling
phases. The initial trauma provokes an inflammatory
response, involving the release of a variety of substances
including fibronectin, growth factors, fibroblasts, endothe-
lial cells, and osteoblasts, which act to fill the fracture gap
with granulomatous tissue. The reparative phase involves a
periosteal response with angiogenesis and formation of
connective tissue and soft callus, which is gradually
replaced by immature woven bone via intramembranous or
endochondral bone formation. In the final remodeling
phase, the woven bone callus is gradually replaced by
lamellar bone.
Patients with osteoporosis are significantly more likely
to suffer a fracture than the general population, and
management of these fractures remains a major challenge
in orthopedics [1]. Whether osteoporotic bone has an
increased healing time and a higher risk of non-union is
still under debate; however, osteoporotic bone does have an
impaired ability to hold screws due to cortical thinning,
rarefied trabecular structure, and the presence of voids due
to the crushing of cancellous bone after fracture reduction
[2]. This complicates surgery, and failure rates of fracture
fixation in osteoporotic bone range from 10% to 25% [3].
Any pharmacological intervention that improves bone
repair, fracture healing, and implant fixation (i.e., osseo-
integration) would therefore constitute a considerable
advance in reducing osteoporosis-associated morbidity.
Indeed, while the main goal of osteoporosis treatment is to
prevent fracture, it should also ideally have a positive, or at
least neutral, effect on bone repair.
Many drugs affect the processes of bone repair [4].
Some have a negative effect, such as glucocorticoids and
nonsteroidal anti-inflammatory drugs (NSAIDs), which act
on the vascular supply during the inflammatory phase. The
delay in fracture healing under NSAIDs is mostly based on
numerous animal experiments and retrospective studies in
humans, but randomized controlled trials (RCTs) have
failed to confirm this effect up to now [5]. A number of
drugs have been surmised to have positive effects, such as
growth factors and prostaglandins; but there is currently no
evidence supporting their clinical application. Osteoporosis
drugs would be expected to affect the remodeling phase of
bone repair but not the inflammatory and reparative phases.
This is an important field of research since patients with
osteoporosis are likely to be receiving an osteoporosis drug
at the time of fracture or to be prescribed one shortly after
the event.
The issue of bone repair has been the subject of two
previous reports from the Group for the Respect of Ethics
and Excellence in Science (GREES) and the European
Society for Clinical and Economic Aspects of Osteoporosis
and Osteoarthritis (ESCEO) [6, 7]. The first paper identi-
fied critical issues for clinical trials in fracture healing [6]
and called for guidelines for trials designed to demonstrate
positive or negative impacts of agents on fracture healing.
A systematic review of the reporting of complications in
orthopedic trials subsequently highlighted the necessity of
such guidelines [8], and two multicenter open cohort
studies have been set up to measure prospectively com-
plication rates in osteoporosis [9].
The multitude of parameters involved makes any impact
on bone repair difficult to measure and study. There is a
considerable amount of data from experimental animal
models of bone repair but little clinical trial evidence. The
second report therefore defined themes for primary study
end points in clinical trials [7]: acceleration of fracture
union combined with faster return to normal function and
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reduction of complication rates. One of the main chal-
lenges in RCTs is the standardization of orthopedic inter-
ventions, which can be highly variable since no two
surgeons act in the same way or with the same level of
surgical expertise [10].
The ESCEO and GREES articles have identified a
number of avenues for research [6, 7], including further
exploration of how osteoporosis treatments act on bone
repair, which is proving to be a complex issue and a rapidly
evolving field [11]. This article is the result of a recent
meeting of an ESCEO working group, which reviewed the
current evidence for an impact of osteoporosis treatments
on bone repair.
Methods
Relevant articles, reviews, and case reports were identi-
fied through a PubMed/MEDLINE search of English-
language articles published between 1990 and March
2011. The search strategy included the terms ‘‘osteopo-
rosis,’’ ‘‘osteoporosis treatment,’’ ‘‘bisphosphonate’’
(‘‘alendronate,’’ ‘‘risedronate,’’ ‘‘zoledronic acid,’’
‘‘ibandronate,’’ ‘‘pamidronate,’’ and ‘‘icandronate’’), ‘‘de-
nosumab,’’ ‘‘SERMs’’ (‘‘raloxifene,’’ ‘‘bazodoxifene,’’ and
‘‘lasofoxifene’’), ‘‘strontium ranelate,’’ ‘‘teriparatide,’’
‘‘PTH,’’ ‘‘sclerostin antibody,’’ ‘‘DKK1 antibody,’’ ‘‘bone
morphogenetic protein,’’ ‘‘fracture healing,’’ ‘‘fracture
union,’’ ‘‘bone repair,’’ ‘‘osseous regeneration,’’ ‘‘osseous
wound healing,’’ and ‘‘osseointegration.’’ Separate sub-
searches were also performed using a cross-search of the
above terms combined as well as the reference lists of the
selected articles. Overall, 330 articles were detected, 71 of
which were selected by the authors for inclusion in this
review.
Bisphosphonates
There has been some debate regarding the impact of bis-
phosphonates on fracture union and bone repair [12, 13].
The concerns are primarily linked to the mode of action of
bisphosphonates, which prevent osteoporotic fracture by
suppression of bone resorption. This might be expected to
have an impact on the third phase of bone repair, i.e., the
remodeling phase [14]. Moreover, oral and intravenous
bisphosphonates are known to be preferentially deposited
at the site of acute fracture [15], which may exacerbate any
action they have on bone repair. The debate has been
fueled by recent case reports of atypical subtrochanteric
fractures in patients receiving long-term treatment with
bisphosphonates [16–18].
Experimental Evidence
The experimental evidence for the effects of bisphospho-
nates in animal models of bone repair and fracture is, on
the whole, positive. There have been studies using a variety
of bisphosphonates, including alendronate [14, 19],
risedronate [20], zoledronic acid [15], pamidronate [21],
and incadronate [22, 23]. Net osteoblast function does not
appear to be impaired [19]. Most studies suggest that
treatment with bisphosphonate is associated with an
increase in callus size and mineralization [15, 21–23] or a
neutral effect [12, 19]. There is no experimental evidence
for a negative effect on callus formation [12]. In fact,
bisphosphonates were often accompanied by an increase in
callus mechanical strength compared with control animals
[15, 19, 21]. According to some results, treatment with
bisphosphonate slows callus remodeling and the removal of
cartilage, which may delay the completion of the fracture-
healing process [14, 19]. On the other hand, other results
suggest that bisphosphonates do not affect long bone–
fracture healing in the long term [23], though they may
delay the remodeling process in the immediate postfracture
period. A study with zoledronic acid found that the timing
of administration was important and that delaying admin-
istration by 2 weeks produced larger and stronger callus
[15]. It appears that delayed injection increased uptake
efficacy of the agent in the callus.
The effect of bisphosphonates on osseointegration and
implant fixation has been investigated in a variety of ani-
mal experiments [13]. In one study involving implantation
of pamidronate-coated screws into the tibia of Sprague–
Dawley rats, local application of bisphosphonate was found
to improve pull-out force by 28% after 2 weeks
(p = 0.0009 vs. control) and pull-out energy by 90% [24].
These results were confirmed in a similar rat model with
ibandronate, in which either local or systemic application
of the bisphosphonate improved screw fixation [25].
Clinical Evidence
Data from a double-blind RCT on the impact of bis-
phosphonate treatment on fracture healing, from the
HORIZON (Health Outcomes and Reduced Incidence with
Zoledronic Acid Once Yearly) Recurrent Fracture trial in
patients after hip fracture [26], which included blinded and
centralized adjudication of hip radiographs and clinical
files, have recently become available. Delayed fracture
healing was defined according to clinical criteria (persistent
pain or inability to bear weight) and radiographic criteria at
least 6 weeks after surgical repair (persistence of fracture
line, appearance of new fracture line, displacement of
fracture, or lack of callus formation or fracture consolida-
tion) [26]. The results indicated no significant difference in
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delayed hip fracture healing defined according to these
criteria with zoledronic acid (34 cases [3.2%] vs. 29 cases
[2.7%] on placebo, p = 0.61). This applied even when the
drug was infused in the immediate postoperative period,
and multivariable logistic regression confirmed that there
was no association between timing of administration and
risk for delayed fracture repair with use of zoledronic acid
(odds ratio [OR] = 1.21, 95% confidence interval [CI]
0.74–1.99, p = 0.44) [27]. While these data are reassuring
with respect to the use of bisphosphonates in patients after
fracture, they should be treated with some caution. For
example, the HORIZON population had one-third of the
mortality of a typical hip-fracture population and, there-
fore, constituted a relatively ‘‘healthy’’ subset of the hip-
fracture population. Nevertheless, particular strengths of
the study included its prospective design and double-blind
character, with well-defined and well-assessed end points
as well as independent and blinded adjudication.
Two small placebo-controlled studies indicated that
1-year treatment with alendronate could prevent bone loss
after fracture and did not affect fracture healing [28, 29].
On the other hand, data from small studies and retrospec-
tive case–control studies with bisphosphonates have been
less consistent but should be considered with caution due to
potential confounding by unmeasured determinants of
fracture healing and because most studies used a case–
control design [30, 31]. One retrospective study in 19,731
patients with humeral fracture suggested that use of bis-
phosphonates doubled the risk for fracture non-union [32].
In this study, fracture non-union was defined as patients
receiving an orthopedic intervention related to non-union
91–365 days after the initial fracture; it proved to be rare
and occurred in 0.4% of the sample (81 cases, of whom
16% received a bisphosphonate after the fracture). Adjus-
ted multivariable regression analysis suggested that use of
a bisphosphonate in the postfracture period might be
associated with an increased risk for non-union
(OR = 2.37, 95% CI 1.13–4.96), though the conclusions of
this study are limited by the small number of fractures and
its cross-sectional design [32].
The clinical effect of oral bisphosphonate on osseoin-
tegration has been explored in trials in postmenopausal
women with osteoporosis [33], in which patients with
internal fixation of a pertrochanteric fracture were ran-
domly allocated to alendronate 70 mg/week orally or
control. The removal torque for the screws was two times
higher in the treatment group, indicating improved osseo-
integration. Other studies with ibandronate and clodronate
have shown that both systemic and local perioperative
treatment with bisphosphonate can improve the fixation of
total knee prostheses [34, 35].
There is an association between atypical subtrochanteric
stress fracture and alendronate use [18]. The incidence of
this type of fracture is very low. Possible mechanisms
include accumulation of microdamages, decreased repair,
suppression of turnover, and increased mineralization.
In conclusion, there is RCT evidence that bisphospho-
nate treatment after the fracture does not delay fracture
healing, even following hip-fracture surgery or when the
drug is administered in the immediate postoperative period.
Local or systemic application of bisphosphonate may
improve osseointegration. The impact of bisphosphonates
prior to fracture on fracture healing is unknown.
Denosumab
There has been one experimental study in animals of the
impact of denosumab, the fully human monoclonal anti-
body against the RANK ligand (RANKL), on fracture
healing [19]. Denosumab is a potent inhibitor of osteoclast-
mediated bone resorption and would, therefore, be expec-
ted to have similar properties to the bisphosphonates. The
effects of denosumab were therefore compared with those
of alendronate in male huRANKL knock-in mice [19].
There was no effect of denosumab or the bisphosphonate
on fracture union or initial callus formation in this animal
model. Both agents were found to delay callus remodeling,
though callus strength and stiffness were greater in treated
animals than in controls [19]. The authors concluded that
neither intervention had negative implications for short-
term repair of fracture. To our knowledge, there are no
studies on denosumab and osseointegration.
More recently, the effect of denosumab on fracture
healing was tested in the FREEDOM trial, in the subset of
199 patients with incident nonvertebral fractures [36]. In
this double-blind, placebo-controlled analysis, the use of
denosumab was not asociated with delayed healing or with
any complications following fracture or surgical manage-
ment, providing further support to the concept that even
potent antiresorptive treatment does not interfere with
fracture healing.
Selective Estrogen Receptor Modulators: Raloxifene
The effects of selective estrogen receptor modulators
(SERMs) on bone repair, fracture healing, and osseointe-
gration remain unclear. One experimental animal study in
ovariectomized rats showed that raloxifene did not have an
impact on progression of fracture repair [14], with similar
radiographic assessments and biomechanical properties to
sham-operated animals. Similar properties were found for
estrogen. By contrast, a very recent study in a rat model of
metaphyseal fracture indicated improved healing in oste-
oporotic bone with raloxifene and estrogen with regard to
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callus formation, resistance, and elasticity [37]. On the
basis of the limited nonclinical data available, we conclude
that raloxifene (like estrogen) has a modest, if any, effect
on fracture healing. To our knowledge, there is no clinical
evidence for an impact of SERMs on bone repair.
Parathyroid Hormone
Agents with bone-forming properties would be expected to
find applications in reconstruction of bone postfracture.
The anabolic agent teriparatide (recombinant human
parathyroid hormone [PTH] 1–34) is a potent anabolic
agent that stimulates osteoblastic proliferation and differ-
entiation, leading to an increase in bone mass. There is a
large amount of experimental evidence for the impact of
teriparatide on bone repair [38], and it is currently the only
osteoporosis treatment for which an RCT in fracture
healing has been completed.
Experimental Evidence
The first animal study of teriparatide in fracture healing
was reported more than a decade ago by Andreassen et al.
[39]. They induced a unilateral tibial fracture in intact rats
administered teriparatide at the daily dose used in osteo-
porosis (60 lg/kg) or at a higher daily dose (200 lg/kg).
After 20 and 40 days, the higher dose of teriparatide
enhanced callus volume (?99% and ?72%, respectively)
and mechanical strength (ultimate load, ?75% and
?175%), while the lower dose had no influence at 20 days
but increased callus volume (?42%) and mechanical
strength (?132%) of the fractures after 40 days [39]. These
changes were significantly different from vehicle at 20 and
40 days for the higher dosage of teriparatide (all p \ 0.01)
and at 40 days for the lower dosage (both p \ 0.01) [39].
These experiments were followed by a large number of
studies demonstrating that teriparatide increases callus
formation and improves biomechanical strength of healing
fracture in young and aged rats [40, 41], young male rats
[42], ovariectomized rats [43, 44], and rabbits [45]. It was
also shown to improve skeletal repair by enhancing
external callus volume, total bone mineral content, bone
mineral density (BMD), and cellular content of the callus
[40–42, 44, 46].
Mechanistic studies in rats with a unilateral femoral
shaft fracture indicate that teriparatide enhanced callus
formation by the early stimulation of proliferation and
differentiation of osteoprogenitor cells. The same workers
detected increased production of bone matrix proteins and
osteoclastogenesis during callus remodeling [42]. There is
also evidence for an effect in the earliest stages of endo-
chondral bone repair from a study in mice with closed
femoral fractures [47]. Treatment with teriparatide was
associated with increased chondrocyte recruitment and rate
of differentiation in the fracture callus, as well as increased
callus volume. Expression of the Wnt-signaling genes was
increased in teriparatide-treated mice, indicating that the
effects of the agent are mediated, at least in part, by the
Wnt-signaling pathways.
In the largest study of fracture repair performed in a rat
model, 270 animals underwent closed femoral fracture
followed by 5 or 30 lg/kg daily teriparatide or vehicle
[46]. After 3 weeks, callus formation significantly
improved in animals administered 30 lg/kg daily teri-
paratide, in terms of torsional strength, stiffness, bone
mineral content, BMD, and cartilage volume (all p B 0.05
vs. control). After 5 weeks, all the animals had significant
increases in bone mineral content, BMD, and total osseous
tissue volume (all p B 0.05 vs. control) and decreases in
void space and cartilage volume (both p \ 0.05). Torsional
strength was increased at 5 weeks in animals treated daily
with 30 lg/kg (p \ 0.05). Even though treatment with
teriparatide was stopped at 5 weeks, there were sustained
increases in torsional strength and BMD after 12 weeks in
the 30 lg/kg group vs. controls (all p B 0.05). There was
no change in osteoclast density, suggesting that teriparatide
enhanced bone formation but did not induce bone resorp-
tion. The authors concluded that teriparatide enhances
fracture healing by increasing mineralization, BMD, and
strength throughout the remodeling phase of fracture
healing [46]. This study was also instrumental in defining
the lower effective dose of 5 lg/kg daily teriparatide.
Teriparatide has been demonstrated to enhance spinal
fusion [48, 49]. Spinal fusion is used to manage spinal
deformity or instability but can often result in pseudar-
throsis. The impact of teriparatide on spinal fusion was
investigated in a rabbit model [48] involving bilateral
posterolateral spine fusion, followed by daily treatment
with 10 lg/kg teriparatide (n = 22 rabbits) or saline only
(n = 22 rabbits) for 6 weeks. At the end of the study,
fusion was observed in 81% of the teriparatide-treated
rabbits vs. 30% of controls (p \ 0.001). Radiographic
images for each L5–L6 spinal segment were scored using a
five-point scale (0 = no bone, 5 = definite fusion), which
showed an average score of 4.51 for teriparatide vs. 3.36
for control (p = 0.001) [48]. Histology and computed
tomographic imaging showed more bone and cartilage in
the treated than the untreated specimens.
The fixation of an orthopedic implant depends partly on
the growth of bone at the interface (osseointegration),
which may be promoted by a bone-forming agent. This has
been explored for teriparatide in a study in which stainless
steel screws were implanted in the tibia of rats receiving
60 lg/kg daily teriparatide (n = 14) or vehicle (n = 14)
[50]. After 4 weeks of treatment, the removal torque of
J. Goldhahn et al.: Fracture Healing with Current and New Osteoporosis Treatments 347
123
screws implanted in the teriparatide animals was three
times greater than in controls (3.5 vs. 1.1 Ncm, p = 0.001)
and the pull-out force was more than doubled (145 vs.
66 N, p = 0.002). Histological analysis showed a greater
density of trabecular bone around the implant with teri-
paratide. The results indicate that teriparatide may enhance
osseointegration and the early fixation of orthopedic
implants. A recent article has shown a remarkable potential
of teriparatide as an adjuvant therapy for allograft repair in
a mouse model of large femoral defect reconstruction [51].
Clinical Evidence
There are a growing number of case reports on the effects
of teriparatide on fracture healing [52–54]. These report
positive effects of teriparatide on healing in patients with
hip fracture [54] or delayed union of a fracture of the spine
or extremities [53]. There is also a report from an obser-
vational cohort of 145 patients with complicated fractures
in a number of different anatomical sites (including spine
and extremities) [38]. Treatment with 20 lg/day teripara-
tide was associated with resolution of pain or evidence of at
least partial fusion within 12 weeks in 141 patients (97%).
There have been two randomized trials of teriparatide in
fracture healing. One was a placebo-controlled, random-
ized, blinded, multinational trial in 102 postmenopausal
women with a dorsally angulated distal radial fracture in
need of closed reduction but not surgery. The patients were
randomly allocated to receive placebo or 20 or 40 lg/day
of teriparatide. The primary end point was the median time
from fracture to first radiographic evidence of complete
cortical bridging in at least three cortices. Median time to
healing was 7.4 weeks with teriparatide 20 lg/day,
8.8 weeks with teriparatide 40 lg/day, and 9.1 weeks in
the placebo group [55]. Whereas no significant difference
between high-dose teriparatide (40 lg/day) and the control
group could be detected (p = 0.52), post hoc analysis
showed that the difference from placebo was significant for
patients receiving teriparatide 20 lg/day (95% CI –2.7 to –
0.6 weeks, p = 0.006). Another post hoc analysis excluded
nine patients who did not meet inclusion criteria on blinded
evaluation of radiographs. Again, in this new sample, there
was no difference in time to healing between high-dose
teriparatide and placebo (p = 0.127), but there was a sig-
nificant difference between low-dose teriparatide and pla-
cebo (95% CI –2.8 to –1.2 weeks, p \ 0.001) and low-dose
vs. high-dose teriparatide (95% CI –2.7 to –0.4 weeks,
p \ 0.03) [55].
The finding of an effect for the lower, but not the higher,
dosage was unexpected [55] and may simply illustrate the
difficulties in carrying out RCTs in fracture healing. A
subgroup analysis of callus formation on 5-week radio-
graphs from 27 patients in one center indicated that
teriparatide may have a dose-dependent effect on callus
formation [56]. The results suggest that radiographic
quality at an early time point may be a sensitive variable,
rather than time to cortical continuity [56].
The other RCT with teriparatide was a placebo-controlled
study of osseous regeneration in 40 patients with periodon-
titis [57]. All patients underwent periodontal surgery and
received either placebo or 20 lg/day teriparatide for
6 weeks. The primary end point was a radiographic linear
measurement of alveolar bone level. After 12 months,
patients treated with teriparatide had improved clinical out-
comes, greater resolution of alveolar bone defects, and
accelerated osseous wound healing in the oral cavity [57],
with a mean linear gain in bone of 29% vs. 3% in the placebo
group (p \ 0.001). The authors concluded that teriparatide
given in conjuction with periodontal surgery may be useful
for the management of localized bone defects in the jaw [57].
In a prospective RCT, the effects of 100 lg/day of
PTH(1–84) on pelvic fracture healing and functional out-
come were evaluated in postmenopausal women. This
treatment accelerated fracture healing, 7.8 vs. 12.6 weeks
(p \ 0.001), and improved the clinical outcome as evi-
denced a lower pain visual analog scale score and a better
Timed Up and Go test [58].
In conclusion, there is clinical evidence for an effect of
teriparatide in fracture healing. Anecdotal case reports
cannot be considered as clinical proof, and interpretation of
the RCT is hampered by the absence of an effect of the
higher dose. However, the evidence is consistent with a
positive impact of 20 lg/day teriparatide on clinical frac-
ture healing and fracture non-union, and this is supported
by the preclinical investigations which suggest a faster
healing process with this agent. Further RCTs of teripara-
tide in fracture healing are clearly a priority.
Strontium Ranelate
There have been a number of experimental studies inves-
tigating the impact of strontium ranelate on bone repair,
and there is some evidence for a clinical effect but no
completed RCTs yet.
Experimental Evidence
Studies in animal models of fracture healing indicate that
treatment with strontium ranelate is associated with
improved bone microstructure, callus volume, and biome-
chanical properties [59–61], associated with a more mature
and tightly arranged woven or lamellar bone after
2 months.
In one study, in ovariectomized rats with bilateral
transverse osteotomy of the proximal tibiae [59], rats
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treated with strontium ranelate (450 mg/kg daily) had
higher BMD than controls (?28% at 4 weeks, p \ 0.01,
and ?16% at 8 weeks, p \ 0.05), and histology revealed
that they also had increased bone formation and bone
volume as well as improved microstructure. Although
microcomputed tomography showed the fracture gap at
4 weeks had transformed into bony union at 8 weeks in all
animals, those treated with strontium ranelate had more
mature callus and a higher degree of mineralization at
8 weeks. These changes were associated with increases in
the strength and stiffness of bone (?211% ultimate load
and ?75% stiffness vs. controls at 4 weeks, both p \ 0.01)
[59].
These observations have been confirmed in a rat model
of osteoporosis, which demonstrated increased mechanical
strength and fracture stiffness with strontium ranelate,
again with more mature woven bone [60]. The difference
was shown to be significant by histological grading, for
which the 20 animals treated with strontium ranelate scored
8.0 ± 0.8 (grade 8 = entirely woven bone) and the 20
control animals scored 6.6 ± 2.2 (grade 6 = equal
amounts of cartilage with some woven bone, grade
7 = predominantly woven bone with some cartilage)
(p = 0.038 between groups). These workers also graded
the callus radiographs using the Goldberg classification
(stage 2 = possible union, stage 3 = complete union) and
found higher scores for the strontium ranelate group than
controls (2.7 ± 0.6 vs. 2.2 ± 0.7, p = 0.001) [60].
There is one comparative study of strontium ranelate
and teriparatide in 60 ovariectomized rats with a closed
diaphyseal fracture [61] divided into four groups (strontium
ranelate, n = 15; teriparatide, n = 15; no treatment,
n = 15; and sham, n = 15). Strontium ranelate signifi-
cantly improved the resistance of callus to torsional load
after 4 weeks (?44%, p \ 0.05 vs. ovariectomized rats),
an effect less apparent with teriparatide (?20%, nonsig-
nificant) [61]. Both treatments increased bone volume of
the callus (?46% with strontium ranelate and ?32% with
teriparatide, both p \ 0.05 vs. ovariectomized rats), but
only strontium ranelate led to a significant increase in
callus tissue volume (?32% with strontium ranelate,
p \ 0.01 vs. ovariectomized rats; ?6% with teriparatide,
nonsignificant).
These preclinical data support the concept of improved
fracture healing with strontium ranelate. On the other hand,
the results contrast with a study that failed to find any
beneficial or harmful effects of strontium ranelate on
traumatically induced fracture healing in intact rats [62].
Animal studies have also shown that strontium ranelate
significantly improves implant osseointegration. One study
in rats receiving strontium ranelate or vehicle for 8 weeks
reported significant improvements in pull-out strength with
strontium ranelate (?34%, p \ 0.05 vs. control) [63].
Moreover, the bone surrounding the implant had improved
biomechanical properties in both cortical (?12% modulus
and ?13% hardness) and trabecular (?7% modulus and
?17% hardness) areas. Microarchitectural improvements
comprised increased bone volume/total volume (?36%),
trabecular thickness (?13%), and connective density
(?23%) (all p \ 0.05 vs. control) with a more plate-like
structure and better bone-to-implant contact (?19%,
p \ 0.05) [63]. These effects were dose-dependent, with
significant correlations between microcomputed tomo-
graphic results (trabecular parameters and bone volume/
total volume) and biomechanical properties (push-out
force) [64].
Clinical Evidence
There are several case reports supporting a beneficial
impact of strontium ranelate on fracture healing and frac-
ture non-union [65, 66] but no RCT evidence yet. One of
these reports described two cases of apparent fracture
healing with strontium ranelate in postmenopausal women
with osteopenia or osteoporosis and previous delayed union
[66]. There are also four cases of non-union of complicated
long bone fractures for up to 20 months, which had all
failed to respond to conventional management, including
internal and/or external fixation [65]. Treatment with
strontium ranelate for between 6 weeks and 6 months
appeared to facilitate the consolidation of these fractures.
These case reports need to be interpreted with some cau-
tion; however, they do underline that the influence of
strontium ranelate in fracture healing merits further
investigation in controlled trials.
Future Agents and Bone Repair
There is no clinical evidence for an impact on bone repair
for any of the agents currently in development for the
management of osteoporosis. There is experimental evi-
dence for some of these agents, notably sclerostin antibody
and DKK1 antibody. On the other hand, bone morphoge-
netic proteins (BMPs) were developed to directly promote
bone healing.
The protein sclerostin is secreted by osteocytes and acts as
a negative regulator of osteoblasts and bone formation.
Sclerostin antibody has been shown to induce an increase in
bone formation and bone mass and strength without an
impact on resorption [67]. In view of its anabolic mode of
action, sclerostin antibody is currently in phase 2 develop-
ment for the treatment of conditions with low bone mass and
fracture healing. It has been tested in a variety of experi-
mental models of bone healing, and preliminary results
support a positive impact of the agent on fracture repair and
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gap defects. There is one report of a study on the regeneration
of traumatized metaphyseal bone in rats, in which sclerostin
antibody enhanced implant fixation with significant differ-
ences in pull-out strength at 2 and 4 weeks vs. control (38%
and 56%, respectively; both p \ 0.005) [68]. The authors
concluded that sclerostin antibody improves mechanical
fixation of cancellous bone and suggested that this implies a
general ability to form more bone, rather than a specifically
improved response to fracture. Further research is likely to
elucidate whether these preclinical results will translate into
clinical applications.
A number of targets on the Wnt-signaling pathway are
currently being tested for therapeutic applications in the
management of osteoporosis [69]. There are no clinical
data on fracture healing, though the preclinical data have
revealed some interesting points. For example, experiments
in a transgenic mouse model demonstrated that b-catenin
levels are low in intact bone tissue but remain high during
the entire period of fracture repair, with the cellular levels
depending on time after fracture [70]. Many Wnt ligands
were expressed during fracture healing and appear to play a
major role. Treatment with DKK1 (an antagonist of the
Wnt/b-catenin pathway) impaired b-catenin signaling and
fracture healing, while mice expressing an activated form
of b-catenin in osteoblasts showed markedly enhanced
bone healing. Interestingly, treatment with lithium
activated b-catenin in the healing fracture, though healing
was enhanced only when lithium treatment was started
subsequent to fracture [70]. The possibility that lithium
could improve fracture healing is intriguing, though the
implications of the timing of administration need further
investigation. In this context, the effect of treatment with
another agent modulating Wnt signaling has also been
reported to depend on timing of treatment initiation. A
study in LRP5 knockout mice reported that DKK1 antibody
enhanced fracture repair when it was administered imme-
diately after fracture but not when it was administered after
a further 4 days [71].
Growth factors can stimulate one or more steps in
endochondral and intramembranous bone formation. The
potential of BMPs has been the subject of a large amount of
research, and they are commercially available for local
administration [4]. The effect of local administration of
BMPs was the subject of a recent Cochrane review
including 11 RCTs [72]. Apart from one study, time to
tibial fracture healing was comparable between the BMP
and control groups. There is some evidence for increased
healing rates vs. usual care in acute tibial fracture (risk
ratio [RR] = 1.19, 95% CI 0.99–1.43) but no evidence for
beneficial effects in patients with non-union (RR = 1.02,
95% CI 0.90–1.15) [72]. The role of BMP in fracture non-
union remains unclear, and further research is necessary.
Table 1 Effect of currently available osteoporosis treatments on bone repair
Agent Effect on bone repair
Experimental evidence Clinical evidence
Bisphosphonates Increased callus size and mineralization Retrospective data, but not RCT data, indicate increased risk for delayed
healing
Reduced callus remodeling Impact of use prior to fracture on fracture healing unknown
Improved mechanical strength One large RCT does not show any impairment in fracture repair
Local and systemic application may improve implant fixationImproved implant osseointegration
Denosumab Delayed remodeling Post hoc analysis of one RCT showed no effect on fracture healing
Improved callus strength and stiffness
SERMs Modest improvement in callus formation,
resistance, and elasticity
None
Teriparatide Increased callus formation Case reports suggest benefit on fracture healing
Increased callus volume, mineralization, and
cellular content of callus
RCT in patients with distal radial fractures demonstrated a benefit for
20 lg/day (but not 40 lg/day) on radiographic healing
Improved biomechanical strength, including
torsional strength and stiffness
RCT in patients with severe chronic periodontitis showed a benefit of




Improved callus resistance and volume Case reports suggest benefit on fracture healing
Improved bone microarchitecture
Improved biomechanical properties, including
strength, stiffness, and ultimate load
Improved implant osseointegration
BMD bone mineral density, RCT randomized controlled trial, SERM selective estrogen receptor modulator
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Conclusion
The evidence for the effects of osteoporosis drugs on bone
repair and fracture healing is overall positive. Experimental
studies indicate that teriparatide and strontium ranelate
may have a favorable impact on fracture repair, and there
are signs that these effects may potentially translate into
therapeutic applications. There is no evidence that short-
term treatment with the antiresorptive agents (bisphos-
phonates, SERMs, or denosumab) is detrimental to fracture
repair, though the impact of long-term therapy is unknown.
The effects of currently available osteoporosis agents in
terms of experimental and clinical evidence for bone repair
and fracture healing are summarized in Table 1.
Despite promising results, there remain a number of
issues for the research agenda for fracture healing in
osteoporosis. First, there is a paucity of epidemiological
data on fracture healing and complication rates in patients
with osteoporosis, which hampers measurement of phar-
macological effects. Accurate epidemiological study of
fracture, osteoporotic or otherwise, is difficult due to
widely differing coding systems between hospitals and
variations in the criteria for good functional outcome [73].
Delayed union appears to be likely in 5–10% of cases. The
risk of non-union is increased by local factors, such as poor
contact, biomechanical instability, and the magnitude of
the injury, as well as a number of systemic conditions (e.g.,
osteoporosis, diabetes, or NSAID use). Further research is
therefore needed to provide more accurate data on epide-
miology as well as the natural course of the disease [8, 9].
In this context, more research is also necessary into the
impact of delayed fracture healing on health economics and
the cost-effectiveness of treatment, for example, a measure
of the economic impact of a patient spending less time in
hospital due to pharmacological fracture healing.
Second, it is proving extremely difficult to transpose the
plethora of promising results in small animal models to
humans. This may be related to a number of factors. For
example, many of the animal models are in normal bone
and not in osteoporosis. Moreover, osteopenia is not oste-
oporosis, ovariectomy is not menopause, and cortical bone
is mechanically different from cancellous bone. Better
understanding of how the mechanical and biological pro-
cesses work could lead to improved definition of animal
models as well as boundary conditions and, possibly, new
therapeutic targets.
Third, some of the results suggest that the timing of
administration may play an important role in the pharma-
cological management of fracture. This is most likely due
to the large number of pathways involved in the phases of
bone repair and should be explored in greater depth to
resolve questions surrounding when the treatment might
best be administered.
Finally, surgical decisions and expertise could markedly
change the impact of pharmacological treatment, particu-
larly if the treatments affect both fracture healing and
orthopedic fixation with screws. This issue is closely tied to
the quantitative evaluation of fracture healing in RCTs
[11]. A related problem is difference in the impact on bone
repair for differing fracture sites (e.g., radius, tibia, or hip)
or bone types (cortical or cancellous bone). There are
currently no guidelines on whether results at one site can be
extended to all others. This is an important point given the
relative difficulties in recruiting patients with very serious
fracture into RCTs.
In conclusion, drugs and bioactive substances will
probably have a role in the future management of fractures.
There is currently no evidence that osteoporosis treatments
have a negative effect on bone repair and some experi-
mental evidence for positive effects on healing, notably for
agents with a mode of action that involves bone formation.
There is an urgent need for better RCT evidence of an
impact of osteoporosis treatments on fracture repair.
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